Dermatology

The Pharmacy Times® Dermatology resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?

FDA OKs Dupilumab Indication for Adolescents with Atopic Dermatitis

With this approval, dupilumab (Dupixent) offers a biologic therapy option for patients 12 to 17 years of age who have moderate-to-severe atopic dermatitis.

What is the Most Cost-Effective Plaque Psoriasis Treatment?

Approximately 1.7 million insured US patients are burdened with moderate to severe plaque psoriasis.

Biologic Drug Shows Promise Treating Moderate-to-Severe Psoriasis

Tildrakizumab was approved by the FDA as a subcutaneous therapy for patients with moderate-to-severe psoriasis.

Analysis: Dupilumab Improves Quality of Life for Patients With Atopic Dermatitis

Analysis of care in a routine clinical practice setting show that 40-week treatment of biologic dupilumab (Dupixent, Sanofi-Regeneron) plus noncosmetic topical moisturizer (emollient) is associated with significantly improved symptoms and health-related quality of life (HRQoL) in particular patients with atopic dermatitis (AD).

Secukinumab Demonstrates Quality of Life Improvements in Psoriasis Patients

Data from an analysis of multiple phase 3 studies highlight improvements in mobility, self-care, and usual activities for patients with moderate-to-severe psoriasis taking secukinumab (Cosentyx).

Ilumya From Sun Pharmaceutical Industries

The FDA has approved Ilumya (tildrakizum- ab-asmn) from Sun Pharmaceutical Industries Ltd to treat moderate to severe plaque psoriasis.

February 15 Pharmacy Week in Review: Psoriasis Treatment May Help Prevent Heart Disease, Unproven Products Prompt FDA Warnings

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Baricitinib Demonstrates Efficacy in Treating Atopic Dermatitis in Phase 3 Studies

Data from 2 phase 3 trials showed significant improvement in disease activity in patients with moderate-to-severe atopic dermatitis treated with baricitinib (Olumiant).

Psoriasis Patients Without Psoriatic Arthritis Benefit More From Methotrexate

A study of methotrexate in patients with psoriasis found that the immunosuppressive drug was more effective in patients without psoriatic arthritis than those with the added condition.

Guselkumab Shows Superiority in Severe Plaque Psoriasis

Patients administered guselkumab achieved an improvement of 90% or more Psoriasis Area Severity Index score than those administered secukinumab.

Atopic Dermatitis Incidence High Among US Adults

A new study shows high prevalence of atopic dermatitis among adults, illustrating the need for more available treatment options.

Dupixent Granted Priority Review for Atopic Dermatitis in Adolescents

Officials with the FDA have granted Priority Review to dupilumab (Dupixent, Sanofi) for moderate-to-severe atopic dermatitis in adolescent patients aged 12 to 17 years.

The Pharmacy Times® Dermatology resource center provides a source of all the latest clinical information, with articles covering updates from the robust pipeline of novel therapies for the skin, hair, nails, and mucous membranes, as well as the newest data from all phases of clinical trials and studies in the space. It serves as a hub of information and news for dermatologists everywhere.

Among its other resources are a wealth of videos including interviews with thought leaders and experts in dermatology, and moderated panel discussions about the best practices and key methods for treating complex cases of acne, eczema, dermatitis, and dry or sweaty skin.